{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:57:50Z","timestamp":1747209470985,"version":"3.40.5"},"reference-count":13,"publisher":"National Library of Serbia","issue":"5-6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med pregl","MED PREGLED"],"published-print":{"date-parts":[[2011]]},"abstract":"<jats:p>Introduction. This study was aimed at evaluating the safety and efficacy of\n   brinzolamide 1% suspension (Azopt? 1%) and travoprost 0.004% (Travatan?)\n   combined therapy in patients with open-angle glaucoma or ocular hypertension\n   who are in need of additional intraocular pressure lowering. Material and\n   methods. This is a prospective, three-month, open-label, clinical study.\n   Forty patients (80 eyes) with primary open-angle glaucoma or ocular\n   hypertension on Travatan? treatment and with unsatis-factory results in\n   lowering intraocular pressure were included in the study. The qualifying\n   intraocular pressure on previous treatment with Travatan? (at least 6 weeks)\n   was 22-36 mmHg in at least one eye at 8 a.m. intraocular pressure\n   measurements at three eligibility visits. The patients received brinzolamide\n   1% twice a day in addition to travoprost 0.004% given once a day in the\n   evening for 3 months. The follow-up examinations assessing the safety and\n   efficacy of combined therapy of brinzolamide 1% and travoprost 0.004% were\n   performed after 1 and 3 months. Results. Adjunctive therapy with brinzolamide\n   resulted in statistically significant reductions in intraocular pressure from\n   the travoprost baseline at all visits. Treatment with brinzolamide\/travoprost\n   caused statistically significant sustained reduction in intraocular pressure\n   with the reduction of 17.39% (p&lt;0.001) after 4 weeks and 20.08% (p&lt;0.001)\n   after 12 weeks. The intraocular pressure change from the baseline ranged from\n   -3.9 mmHg after 4 weeks to -4.48 mmHg after 12 weeks. The most frequently\n   related adverse effect was abnormal taste and blurred vision. Conclusion.\n   Brinzolamide 1% (b.i.d.) used adjunctively with travoprost 0.004% (q.d.)\n   lowers intraocular pressure significantly compared to travoprost alone. Both\n   drugs were well tolerated and safe in the studied patients.<\/jats:p>","DOI":"10.2298\/mpns1106310b","type":"journal-article","created":{"date-parts":[[2011,7,18]],"date-time":"2011-07-18T10:17:35Z","timestamp":1310984255000},"page":"310-314","source":"Crossref","is-referenced-by-count":0,"title":["Adjunctive therapy with brinzolamide in patients on travoprost treatment"],"prefix":"10.2298","volume":"64","author":[{"given":"Nikola","family":"Babic","sequence":"first","affiliation":[{"name":"Klini\u010dki centar Vojvodine, Klinika za o\u010dne bolesti, Novi Sad"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9689-0703","authenticated-orcid":false,"given":"Veljko","family":"Andreic","sequence":"additional","affiliation":[{"name":"Klini\u010dki centar Vojvodine, Klinika za o\u010dne bolesti, Novi Sad"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandar","family":"Miljkovic","sequence":"additional","affiliation":[{"name":"Klini\u010dki centar Vojvodine, Klinika za o\u010dne bolesti, Novi Sad"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Canadanovic","sequence":"additional","affiliation":[{"name":"Klini\u010dki centar Vojvodine, Klinika za o\u010dne bolesti, Novi Sad"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sava","family":"Barisic","sequence":"additional","affiliation":[{"name":"Klini\u010dki centar Vojvodine, Klinika za o\u010dne bolesti, Novi Sad"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1078","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(00)00538-9"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(01)00873-9"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1097\/00061198-200110000-00010"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(01)01177-1"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(02)01010-2"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(01)00974-6"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1185\/030079905X38222"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0b013e318033b491"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(02)01418-6"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(03)00098-9"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.03.050"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.03.012"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1185\/030079904125004529"}],"container-title":["Medicinski pregled","Medical review"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T09:22:54Z","timestamp":1685352174000},"score":1,"resource":{"primary":{"URL":"https:\/\/doiserbia.nb.rs\/Article.aspx?ID=0025-81051106310B"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":13,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.2298\/mpns1106310b","relation":{},"ISSN":["0025-8105","1820-7383"],"issn-type":[{"type":"print","value":"0025-8105"},{"type":"electronic","value":"1820-7383"}],"subject":[],"published":{"date-parts":[[2011]]}}}